Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Humacyte Inc (HUMA)

Humacyte Inc (HUMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 163,428
  • Shares Outstanding, K 222,019
  • Annual Sales, $ 2,040 K
  • Annual Income, $ -40,830 K
  • EBIT $ -108 M
  • EBITDA $ -101 M
  • 60-Month Beta 2.11
  • Price/Sales 75.29
  • Price/Cash Flow N/A
  • Price/Book 42.90
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.61
  • Most Recent Earnings $-0.13 on 03/27/26
  • Next Earnings Date 05/12/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 193.14% (-0.36%)
  • Historical Volatility 120.28%
  • IV Percentile 86%
  • IV Rank 37.65%
  • IV High 366.53% on 03/09/26
  • IV Low 88.42% on 07/03/25
  • Expected Move (DTE 29) 0.2550 (37.30%)
  • Put/Call Vol Ratio 0.10
  • Today's Volume 161
  • Volume Avg (30-Day) 1,040
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 83,238
  • Open Int (30-Day) 82,339
  • Expected Range 0.4286 to 0.9386

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.10
  • Number of Estimates 1
  • High Estimate $-0.10
  • Low Estimate $-0.10
  • Prior Year $-0.10
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5469 +25.00%
on 03/30/26
1.1700 -41.57%
on 03/18/26
-0.4364 (-38.96%)
since 03/16/26
3-Month
0.5469 +25.00%
on 03/30/26
1.3100 -47.82%
on 03/10/26
-0.4264 (-38.41%)
since 01/16/26
52-Week
0.5469 +25.00%
on 03/30/26
2.9300 -76.67%
on 06/06/25
-0.8664 (-55.90%)
since 04/16/25

Most Recent Stories

More News
Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti , LLC (“KSF”), announces that KSF has commenced an investigation into...

HUMA : 0.6836 (-7.13%)
Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...

HUMA : 0.6836 (-7.13%)
Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update

- Total revenues from sales and research collaborations were $0.5 million for fourth quarter and $2.0 million for full year -  - Purchase commitment received for a minimum of $1.475 million for...

HUMA : 0.6836 (-7.13%)
Humacyte Appoints Rick McElheny as Senior Vice President of Business Development

- Mr. McElheney brings more than 15 of years’ experience in corporate development and alliance management at biopharma companies. -  - He will work with the Company’s leadership team to expand...

HUMA : 0.6836 (-7.13%)
Humacyte To Announce 2025 Fourth Quarter and Year End Financial Results and Provide Business Update on March 27, 2026

DURHAM, N.C., March 23, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial...

HUMA : 0.6836 (-7.13%)
Payroll Figures Due in Canada Next Week

Monday Economic Lookahead Construction spending (delayed report) (Jan.) Featured Earnings ...

CNM : 51.97 (-2.60%)
HUMA : 0.6836 (-7.13%)
CNTA : 39.53 (-0.20%)
AIR : 118.51 (-3.45%)
IMMX : 9.96 (-0.80%)
SA : 31.47 (+1.16%)
CDZI : 4.83 (-1.63%)
SFD : 28.64 (+2.18%)
AGX : 601.83 (-0.76%)
LXEO : 6.58 (-3.24%)
PAYX : 92.13 (+2.07%)
SBC : 4.42 (+1.61%)
Humacyte Receives Symvess® Purchase Commitment for Clinical Evaluation and Outreach Program in the Kingdom of Saudi Arabia

DURHAM, N.C., March 19, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial...

HUMA : 0.6836 (-7.13%)
Humacyte, Inc. Announces Pricing of $20 Million Registered Direct Offering of Common Stock

Net proceeds from the offering will fund the commercialization of Symvess® in the vascular trauma indication and provide funding beyond key milestones such as the upcoming read-out of Phase 3 results...

HUMA : 0.6836 (-7.13%)
Humacyte Submits Marketing Authorization Application for Symvess® in Israel for Vascular Trauma Repair

- Humacyte is also pursuing a mechanism for making Symvess available in Israel on a hospital-by-hospital basis in advance of MAA approval -  - Preparation is underway for expansion of Symvess ...

HUMA : 0.6836 (-7.13%)
Humacyte To Participate in Upcoming Investor Conferences

DURHAM, N.C., March 02, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial...

HUMA : 0.6836 (-7.13%)

Business Summary

Humacyte Inc. is a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale. Humacyte Inc., formerly known as Alpha Healthcare Acquisition Corp., is based in DURHAM, N.C.

See More

Key Turning Points

3rd Resistance Point 0.8222
2nd Resistance Point 0.7911
1st Resistance Point 0.7373
Last Price 0.6836
1st Support Level 0.6524
2nd Support Level 0.6213
3rd Support Level 0.5675

See More

52-Week High 2.9300
Fibonacci 61.8% 2.0197
Fibonacci 50% 1.7385
Fibonacci 38.2% 1.4572
Last Price 0.6836
52-Week Low 0.5469

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.